| Study |
Time |
Treatment group |
Outcome (scale) |
N of Pts |
Baseline Mean |
End of Study |
Absolute Benefit |
Relative Benefit |
| Caborn 2004 |
5‐13 wk |
E: Hylan G‐F 20 |
WOMAC ‐ pain walking on a flat surface (0‐4 Likert) |
113 |
2.12 |
1.20 |
‐0.37 (I) |
‐17.2% (I) |
| |
|
C: Triamcinolone hexacetonide |
|
102 |
2.15 |
1.60 |
|
|
| Caborn 2004 |
14‐26 wk |
E: Hylan G‐F 20 |
WOMAC ‐ pain walking on a flat surface (0‐4 Likert) |
113 |
2.12 |
1.40 |
‐0.37 (I) |
‐17.2% (I) |
| |
|
C: Triamcinolone hexacetonide |
|
102 |
2.15 |
1.80 |
|
|
| Caborn 2004 |
5‐13 wk |
E: Hylan G‐F 20 |
WOMAC physical function (0‐68 Likert) |
113 |
38.60 |
23.50 |
‐5.70 (I) |
‐15.0% (I) |
| |
|
C: Triamcinolone hexacetonide |
|
102 |
37.90 |
28.50 |
|
|
| Caborn 2004 |
14‐26 wk |
E: Hylan G‐F 20 |
WOMAC physical function (0‐68 Likert) |
113 |
38.60 |
25.50 |
‐7.20 (I) |
‐19.0% (I) |
| |
|
C: Triamcinolone hexacetonide |
|
102 |
37.90 |
30.70 |
|
|
| Caborn 2004 |
5‐13 wk |
E: Hylan G‐F 20 |
WOMAC total score (0‐96 Likert) |
113 |
54.00 |
32.70 |
‐8.30 (I) |
‐15.6% (I) |
| |
|
C: Triamcinolone hexacetonide |
|
102 |
53.10 |
40.10 |
|
|
| Caborn 2004 |
14‐26 wk |
E: Hylan G‐F 20 |
WOMAC total score (0‐96) |
113 |
54.00 |
35.60 |
‐8.20 (I) |
‐15.4% (I) |
| |
|
C: Triamcinolone hexacetonide |
|
102 |
53.10 |
42.90 |
|
|
| Caborn 2004 |
5‐13 wk |
E: Hylan G‐F 20 |
Patient global assessment (0‐100 mm VAS) |
113 |
68.40 |
36.70 |
‐14.50 (I) |
‐21.5% (I) |
| |
|
C: Triamcinolone hexacetonide |
|
102 |
67.30 |
50.10 |
|
|
| Caborn 2004 |
14‐26 wk |
E: Hylan G‐F 20 |
Patient global assessment (0‐100 mm VAS) |
113 |
68.40 |
40.30 |
‐16.20 (I) |
‐24.1% (I) |
| |
|
C: Triamcinolone hexacetonide |
|
102 |
67.30 |
55.40 |
|
|
